We discuss screening in this third post on structural biology and structure-based drug design. Compound screening is central to all drug design strategies discussed earlier. The quality of the compounds we identify in this process will be crucial for the discovery project.
Which strategy to choose when planning a drug discovery project? Maybe structure-based design, ligand-based design, or de novo design? These questions are discussed in our series on structure-based drug design in this second post.
Do we need structural biology services companies for drug discovery? In this first post on structural biology and drug discovery, we discuss the basic idea behind the need for structural biology services.
A new consortium aimed at leveraging the partner's technology platforms for accelerating structure-based drug discovery targeting a “weak spot” in the Sars-CoV-2 virus replication machinery, the NSP10 protein.